OncLive TV

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Stephen M. Ansell, MD, PhD, discusses the utility of non–CAR T-cell therapy options in non-Hodgkin lymphoma.

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer. 

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Reva K. Basho, MD, discusses the emergence of bispecific antibodies in HER2-positive breast cancer.

Mikkael A. Sekeres, MD, discusses the goal of transfusion independence in higher-risk myelodysplastic syndromes.

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Brad S. Kahl, MD, discusses the emergence of antibody-drug conjugates in lymphoma.

Julie M. Vose, MD, MBA, discusses future research efforts with CAR T-cell therapy in lymphoma.

Alison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.